AIM ImmunoTech Announces Each Subscription Of Its Previously Announced Rights Offering Now Entitles Holders To Buy One Unit

AIM ImmunoTech Inc. (NYSE:AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced updated terms for its previously announced rights offering (the "Rights Offering").

Each subscription right now entitles holders to purchase one unit (the "Units"), each Unit consisting of one share of the Company's Series G Convertible Preferred Stock (the "Preferred Stock"), and 2,000 Class G Common Stock Purchase Warrants to purchase the Company's Common Stock (the "Warrants") at a subscription price of $1,000 per Unit. Each share of Preferred Stock will be convertible, at the option of the holder at any time, into 1,000 shares of Common Stock, which is equal to the quotient of the stated value of the Preferred Stock ($1,000) divided by the conversion price ($1.00 per share). Each Warrant will be exercisable for one share of Common Stock at an exercise price of $1.00 per share from the date of issuance through its expiration five years from the date of issuance.